In prior studies, we have found an association between the number of TIL infused and the percentage of CD8+ TIL in the infusion product, with outcome to TIL therapy in metastatic melanoma.2 8 In this study, patients treated on the TIL +DC arm received a higher number of TIL on average (p=0.04, figure 1A). The gene discussed is CD8A; the disease is metastatic melanoma.